Inflammatory Bowel Disease: Why Should I Take My Medications? Sunanda V. Kane, MD, MSPH Associate Professor of Medicine Mayo Clinic College of Medicine.

Slides:



Advertisements
Similar presentations
Clinical Management and Adherence Issues in IBD
Advertisements

Managing Crohn’s Disease through Nutritional Intervention
By: Caitie C. and Miranda F.
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Management of Inflammatory bowel disease 8/12/10.
Inflammatory Bowel Disease
HPI A 25 year old Caucasian male presents to your clinic with two month history of crampy abdominal pain and diarrhea. What else would you like to know?
Ulcerative Colitis.
Inflammatory Bowel Disease Ulcerative colitis (UC) Kristina Blaslov Mentor: A. Žmegač Horvat.
CROHN’S DISEASE STJEPAN ĆURIĆ Mentor: A. Žmegač Horvat.
Inflammatory Bowel Disease
Introduction to CCFA Arkansas Chapter and Inflammatory Bowel Diseases.
Inflammatory Bowel Disease Kimberly Persley, MD Digestive Disease Associates of Dallas Presbyterian Hospital of Dallas.
Inflammatory Bowel Disease
DRUG TREATMENT OF INFLAMMATORY BOWEL DISEASE. Objectives Describe the mechanism of action, pharmacokinetics and adverse effects of drugs in IBD.
Crohn’s disease - A Review of Symptoms and Treatment
Pediatric IBD Research
A DVANCES IN I NFLAMMATORY B OWEL D ISEASE presented by The Foundation for Clinical Research in Inflammatory Bowel Disease
UC. Ulcerative Colitis ( UC ) Ulcerative colitis is an inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract It is.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
Inflammatory Bowel Diseases Dr. Nematollah Ahangar Assistant Prof. of Pharmacology.
Crohn’s Disease Allie Abraham.
Crohn’s Disease Presenting as Intestinal Parasites “I got worms…” Poster by Jared Halterman, Kade Rasmussen DO, and Joseph Dougherty DO A 14 year-old male.
Crohn’s Disease Kyra Alexander. What is it? An inflammatory bowel disease that causes inflammation of the digestive tract. It is an unpredictable disease.
Inflammatory Bowel Disease (IBD)
Nursing Care & Interventions for Clients with Inflammatory Intestinal Disorders Keith Rischer RN, MA, CEN.
Inflammatory Bowel Disease NPN 200 Medical Surgical I.
By: Leon Richardson Period 2
Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Prof. Hanan Hagar Pharmacology Department College of Medicine.
Inflammatory Bowel Disease Francisco A. Sylvester, MD Associate Professor of Pediatrics.
CROHN’S DISEASE Alison Cunliffe. What is Crohn’s Disease?  Chronic inflammatory disease of the intestines  Causes ulcerations, breaks in the lining,
Ulcerative colitis.
“Antibiotics and corticosteroids: Indications and approaches”
Dr. Gholam Reza Khatami Ulcerative colitis is a chronic gastrointestinal disease Given modern treatment, medical management is not curative.
Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Prof. Hanan Hagar Pharmacology Unit College of Medicine.
Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.
IBD Patient Update Case Vignettes 12 November 2011.
An Autoimmune Disorder  Crohn’s disease is inflammation of the digestive system that results from an abnormal immune response.  A cure has not yet.
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Profs. Alhaider and Hanan Hagar Pharmacology Department College of Medicine.
CROHN’S DISEASE By: Omekia Wilkes. What is Crohn’s Disease?  Crohn’s disease is a type of inflammatory bowel disease that affects the intestines.  The.
It's Time A 63-year-old woman was admitted because of severe abdominal pain, fatigue and bloody diarrhea.
Cronhns & Ulcerative Colitis
DIGESTIVE SYSTEM the gastrointestinal tract (GI tract), digestive tract, guts or gut is the system of organs within multicellular organisms that takes.
Sponsors Crohn’s & Colitis Foundation of America Our Mission: To cure Crohn’s disease and ulcerative colitis, and to improve the quality of life of children.
Chronic inflammatory Bowel Diseases By Prof. Abdulqader Alhaider 1432 H.
ULCERATIVE COLITIS. Ulcerative colitis is an idiopathic chronic inflammatory disease of the colon that follows a course of relapse and remission. In a.
1 Ian Leidner, Philip Sidiroglou, Krenare Rexhaj, Alexander Fishman, Yesbel Herrera.
IBD Treatment: The Basics
Crohn’s Disease BY: Brent Movson, Allison Cobb, Alma Hernandez.
By: annie cantrell 5th hour
DISEASES OF SMALL INTESTINE. PLAN CROHN’S DISEASE (CD) Etiology and Etiology and Epidemiology of CROHN’S DISEASE Pathology of CROHN’S DISEASE Pathology.
 2 MAJOR GROUPS : 1. ULCERATIVE COLITIS – colon involved 2. CROHN’S DIDEASE – the hole GI tract EPIDEMIOLOGY  most common in whites than in blacks and.
Drugs used in inflammatory bowel disease and biological and immune therapy of IBD Prof. Hanan Hagar Pharmacology Unit College of Medicine.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Anatomy and Physiology & Pathophysiology
Inflammatory Bowel Disease Crohn’s Disease And Ulcerative Colitis.
Kim Eastman RN,MSN, CNS. INFLAMMATORY BOWEL DISEASE  OVERVIEW  IMMUNOLOGIC DISEASE THAT RESULTS IN INTESTINAL INFLAMMATION  ULCERATIVE COLITIS  CROHN’S.
Crohn's Disease. Crohn'sDisease Crohn's Disease What is it? What is it? What are the causes? What are the causes? What are the treatment options? What.
Page  2 Accutane, a medication used to treat acne, has recently been linked to dangerous health conditions such as inflammatory bowel disease (IBD).
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University.
Prof. Hanan Hagar Pharmacology Unit College of Medicine
ULCERATIVE COLITIS Dr.Mohammadzadeh.
Inflammatory Bowel Disease
Crohn´s disease Domina Petric, MD.
Basics of PSC Christopher L. Bowlus, MD
Lecture 12 Gastrointestinal Disorders Inflammatory Bowel Disease
“Drugs used in IBD and biological and immune therapy of IBD ”
Prof. Hanan Hagar Pharmacology Unit College of Medicine
Presentation transcript:

Inflammatory Bowel Disease: Why Should I Take My Medications? Sunanda V. Kane, MD, MSPH Associate Professor of Medicine Mayo Clinic College of Medicine Rochester, Minnesota

Indeterminate colitis 10%–15% The Spectrum of IBD CROHNS DISEASE –Patchy inflammation –Mouth to anus involvement –Full-thickness inflammation –Variable involvement –Fistulas –Strictures –Extraintestinal manifestations ULCERATIVE COLITIS –Continuous inflammation –Colon only –Superficial inflammation –Variable involvement –Risk of cancer –Strictures (cancer) –Extraintestinal manifestations 1–2 Million Americans

Potential Causes of IBD Genetic Predisposition Immune System Abnormalities Environmental Factors

Environmental Triggers IBD Antibiotics Diet Smoking Infections NSAIDs Stress NSAIDs=nonsteroidal anti-inflammatory drugs.

Diagnosing IBD Clinical history Physical examination Laboratory tests Endoscopy (gastroscopy/colonoscopy) Findings on X-ray films Tissue biopsy (pathology)

Questions Frequently Missed During History-Taking Family history for second-degree relatives NSAID use Antibiotic use Recent/previous infections

Clues in the Physical Examination Clues are present from head to toe –Aphthous oral ulcers –Pale conjunctiva, red eyes –Skin rashes –Abdominal mass –Perianal abnormalities

Ulcerative Colitis Left-sided colitisProctitisPancolitis The small intestine is not involved

Symptoms of Ulcerative Colitis Symptoms depend on extent and severity of inflammation –Rectal bleeding and urgency to evacuate –Diarrhea –Abdominal cramping –Extraintestinal (systemic) symptoms Joint pain/swelling Eye inflammation Skin lesions

Common Symptoms of Crohns Disease Diarrhea Abdominal pain and tenderness Loss of appetite and weight loss Fever Fatigue Rectal bleeding and anal ulcers Stunted growth in children

Laboratory Tests Routine laboratory tests are ordered first –Complete blood count to rule out infection and anemia –C-reactive protein to assess for active inflammation –Chemistry panel for electrolytes and proteins –Thyroid-stimulating hormone for weight loss –Celiac testing of the physicians choice Stool studies –Ova and parasite examinations, but yield may be low –Clostridium difficile toxin –White blood cell count, lactoferrin, and calprotectin

A long stricture in the terminal ileum (Kantors string sign) Diagnostic Studies: Small Bowel Series

Endoscopy Ulcerative colitis Crohns disease

Endoscopy

Management Goals for IBD Relieve symptoms Treat inflammation Treat complications Address psychosocial issues Identify dysplasia and detect cancer Improve daily functioning Replenish nutritional deficits Minimize treatment toxicity Maintain remission Establish Diagnosis

Medical Therapies for IBD 5-aminosalicylic acid (5-ASA) agents –Mesalamine Delayed release tablets, Lialda ® Delayed release tablets, Asacol ® Controlled-release capsules, Pentasa ® Rectal suspension (Rowasa ® enema) Rectal suppository (Canasa ® ) –Sulfasalazine (Azulfidine ® ) –Balsalazide (Colazal ® ) –Olsalazine (Dipentum ® )

Medical Therapies for IBD Antibiotics –Ciprofloxacin (Cipro ® ) –Metronidazole (Flagyl ® ) Steroids –Adrenocorticotropic hormone –Budesonide –Methylprednisolone (Medrol ® ) –Prednisone –Hydrocortisone (Cortenema ®, Cortifoam ® )

Medical Therapies for IBD Immunologic agents –Azathioprine (Imuran ®, Azasan ® ) –6-Mercaptopurine (Purinethol ® ) –Cyclosporine (Neoral ® ) –Methotrexate Biologic agents –Infliximab (Remicade ® ) –Adalimumab (Humira ® ) –Natalizumab (Tysabri ® )

Drugs dont work in patients who dont take them. C. Everett Koop, MD Former US Surgeon General

Factors that Affect Adherence Adherence is taking medications over a long period of time Extent, duration, and severity of disease affect adherence People who are more likely to adhere to therapy –Have more disease flare-ups –Are more knowledgeable about their treatment Clear instructions and educational materials provided by healthcare professionals increases knowledge about –Importance of treatment –Risks of non-adherence Hall A, et al. Gastrointestinal Nurs. 2006;4: Lopez-Sanroman A, Bermejo F. Aliment Pharmacol Ther. 2006;24(Suppl 3): Kane SV. Aliment Pharmacol Ther. 2006;23:

Risk Factors for Non-Adherence Risk FactorOdds Ratio (95% CI) Married 0.46 ( ) Recent procedure 0.96 ( ) Greater extent of disease0.55 ( ) Male gender2.1 ( ) Taking more than 4 medications2.5 ( ) Kane SV, et al. Am J Gastroenterol. 2001;96:

National Quality Forum Report Goals –Improve medication adherence by creating standards to change the way healthcare professionals interact with patients –Develop standard performance measures that could be implemented in patient care settings to improve adherence Recommendations –Adherence needs to be evaluated as a vital sign, every time a patient is seen by a physician or nurse –Ask the questions: Are you taking the medication, how are you taking it, and what is the dose? Traynor K. Am J Health-Syst Pharm. 2005;62:

Significant Factors Associated with Risk of Not Refilling 5-ASA at 3 Months 3,574 UC patients with 5-ASA prescriptions; 1,530 (42.8%) patients did not refill at 3 months. * 12 months prior to index date. Kane S, et al. Gastroenterology. 2007;132(4 Suppl 2):M1033. Rectal 5-ASA* Glucocorticoid use* Copay (per $1 increase) Lower daily pill load (per 1 pill decrease) Male gender Mail order Psychiatric history* Patients More Likely to be Adherent Patients Less Likely to be Adherent

Adherence Decreases Risk of Relapse Patients Remaining in Remission, % Adherent n = Non-adherent n = Time (months)36 From Kane S, et al. Am J Med. 2003;114:39-43; with permission. Adherent Non-adherent

Adherence Decreases Risk of Relapse Kane S, et al. Am J Med. 2003;114: Prospective study in patients with UC in remission and taking mesalamine found chance of remission was –89% in adherent patients –39% in non-adherent patients

Non-Adherence is Associated with Recurrence Follow-up Medication Refilled in Previous 6 Months, % No Recurrence Recurrence From Kane S, et al. Am J Med. 2003;114:39-43; with permission.

Non-Adherence is Associated with Recurrence Kane S, et al. Am J Med. 2003;114: % of patients with recurrence had not taken their medication 34% of patients remaining in remission had not taken their medication

Other Factors that Affect Adherence Adverse reactions to medications Need for many medications Effectiveness of treatment Convenience of treatment Hall A, et al. Gastrointestinal Nurs. 2006;4: Lopez-Sanroman A, Bermejo F. Aliment Pharmacol Ther. 2006; 24(Suppl 3): Kane SV. Aliment Pharmacol Ther. 2006;23:

To Increase Treatment Adherence Simplify the treatment regimen Continue taking the medications Find support for emotional and social issues Hall A, et al. Gastrointestinal Nurs. 2006;4: Lopez-Sanroman A, Bermejo F. Aliment Pharmacol Ther. 2006;24(Suppl 3): Kane SV. Aliment Pharmacol Ther. 2006;23:

Patient-Centered Self-Management Training Robinson A, et al. Lancet. 2001;358: Self-Guided Group Control GroupP-Value Time to treat relapses14.8 h49.6 h< Outpatient visits0.92.9< Time spent visiting a doctor1 h6.2 h< Patients preferred guided self-management over traditional outpatient care Patient-centered self-management resulted in –Earlier treatment of relapses –Fewer hospital and primary care visits –Less time spent during a visit with a doctor

Why Take Your Medications? Possible decreased risk of colorectal cancer Decreased risk of disease progression Increased chance of disease regression Velayos FS, et al. Am J Gastroenterol. 2005;100: Pica R, et al. Inflamm Bowel Dis. 2004;10: Picco MF, et al. Inflamm Bowel Dis. 2006;12: